Cayman Fenofibrate; Purity- Greater Than Or Equal To 98%; Size- 5

Roflumilast N-oxide is an inhibitor of phosphodiesterase 4 (PDE4; IC₅₀ = 2 nM) and an active metabolite of the PDE4 inhibitor roflumilast (Item No. ). It is selective for PDE4 over PDE1-3 and PDE5 (IC₅₀s = >10,000 nM for all). It reduces TNF-α-induced ICAM-1 and eotaxin levels when used in combination with prostaglandin E₂ (PGE₂; Item No. ) in GM06114 human fetal lung fibroblasts (IC₅₀s = 0.9 and 0.5 nM, respectively). It also reduces bFGF-induced and IL-1β augmented proliferation in the same cells. Roflumilast N-oxide (2 nM) reverses cigarette smoke extract-induced reductions in ciliary beat frequency in isolated human bronchial epithelial cells. Roflumilast N-oxide also increases plasma glucagon-like peptide 1 (GLP-1) levels in a glucose challenge in diabetic db/db mice when administered at a dose of 10 mg/kg, as well as prevents increases in blood glucose in db/db mice at 3 mg/kg per day.

WARNING This product is not for human or veterinary use.